COMMUNIQUÉS West-GlobeNewswire

BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026
28/10/2026
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental [...]
ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences
28/10/2026
ProQR to present its ADAR-mediated RNA editing approach and progress toward next-generation editing oligonucleotides at TIDES Europe plenary session AX-0810 Phase 1 data to be featured in two poster presentations at [...]
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
28/10/2026
– Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped. DURHAM, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage [...]
Curabotics Enters National Contract with Capstone Health Alliance, Bringing Robotics and Automation to Hundreds of Hospitals
28/10/2026
Unique agreement gives Capstone's member network direct access to Curabotics' proven automation solutions JACKSONVILLE, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Curabotics , a healthcare technology company dedicated to [...]
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
28/10/2026
FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial [...]
Axogen, Inc. Reports Third Quarter 2026 Financial Results
28/10/2026
Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million ALACHUA and TAMPA, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative [...]
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
28/10/2026
REYKJAVIK, ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
28/10/2026
REYKJAVIK, Iceland, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for [...]
ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026
28/10/2026
Conference Call Scheduled for November 4, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to- [...]
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
28/10/2026
Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritis Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte [...]
NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer
28/10/2026
Biotechnology Executive Brings Extensive Capital Markets, Financing, Corporate Strategy and Investor Relations Experience ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences, Inc. (“NovaBridge” or [...]
Lumexa Imaging Announces Third Quarter 2026 Earnings Conference Call Date
28/10/2026
RALEIGH, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced it will release its third quarter 2026 financial and [...]
BPGbio Publishes Pioneering Research on Novel Brain-Penetrant Therapeutic Candidate for Glioma
28/10/2026
Preclinical study demonstrates potent anticancer activity, blood-brain barrier penetration, and improved survival in glioma models Findings highlight a novel therapeutic approach targeting microtubule dynamics, with [...]
Remix Therapeutics Selected for Late-Breaking Oral Presentation at the 38th EORTC-NCI-AACR Symposium
28/10/2026
Presentation to Include Updated Interim Data from Ongoing Phase 1/2 ARIA Study of REM-422 in Adenoid Cystic Carcinoma WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical- [...]
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
28/10/2026
TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass., Oct. 28, 2026 (GLOBE [...]
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
28/10/2026
DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results [...]
Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia
28/10/2026
BURLINGTON, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system [...]
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
28/10/2026
Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metastases SAN DIEGO and [...]
Beyond the Ballot: More Than 3,500 Back OHIP Petition as Psychotherapy Gaps Come Into Focus
28/10/2026
Following the province’s response to CBC, a Guelph-led campaign asks what happens to people who need treatment outside existing programs. GUELPH, Ontario, Oct. 28, 2026 (GLOBE NEWSWIRE) -- More than 3,500 people have [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum